Corton Capital’s Haemonetics HAE Stock Holding History

Corton Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,471	Closed	-$219K	–	415
2022 Q1	$219K	Buy	+3,471	New	+$189K	0.09%	339

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's HAE Position: Q2 2022 in Review

Corton Capital sold out of Haemonetics (HAE) in Q2 2022, closing a stake of 3,471 shares — an estimated $219K sold.

Corton Capital first reported a position in HAE in Q1 2022 and held it in 1 quarter. The position peaked at $219K in Q1 2022. 241 funds tracked by Wall St. Rank hold HAE as of Q2 2022.

Corton Capital reported no remaining Haemonetics position as of Q2 2022 after selling out during the quarter.
Corton Capital sold 3,471 Haemonetics shares in Q2 2022, an estimated $219K.
Corton Capital first reported a position in Haemonetics in Q1 2022 and held it in 1 quarter.
Corton Capital's Haemonetics position peaked at $219K in Q1 2022.
241 funds tracked by Wall St. Rank held Haemonetics as of Q2 2022.

Based on Corton Capital's 13F filing for Q2 2022, filed 15 Aug 2022.